Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shanghai Henlius Biotech, Inc. Class H ( (HK:2696) ) just unveiled an update.
Shanghai Henlius Biotech, Inc. announced that its biosimilar drug HLX14, a recombinant anti-RANKL human monoclonal antibody injection, has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). This recommendation for approval is a significant step towards gaining centralized marketing authorization across the EU and EEA countries. The positive opinion is based on data demonstrating analytical similarity and clinical efficacy compared to the reference drug, denosumab. This development positions Henlius as a competitive player in the global biosimilar market, with potential implications for stakeholders as the drug progresses towards final approval.
The most recent analyst rating on (HK:2696) stock is a Buy with a HK$61.98 price target. To see the full list of analyst forecasts on Shanghai Henlius Biotech, Inc. Class H stock, see the HK:2696 Stock Forecast page.
More about Shanghai Henlius Biotech, Inc. Class H
Shanghai Henlius Biotech, Inc. is a biotechnology company based in China, focusing on the development of biosimilar drugs. The company specializes in creating treatments for various conditions, including osteoporosis and bone-related diseases, with a market focus on global commercialization except for certain regions in China.
Average Trading Volume: 1,276,778
Technical Sentiment Signal: Buy
Current Market Cap: HK$33.83B
For a thorough assessment of 2696 stock, go to TipRanks’ Stock Analysis page.